Fidia Farmaceutici

What Fidia Farmaceutici does

Fidia Farmaceutici S.p.A. is a privately held Italian pharmaceutical company founded in 1946 and headquartered in Abano Terme (Padua). It specializes in hyaluronic acid (HA) and its derivatives, producing both high and low-molecular-weight HA through proprietary biotechnological fermentation using GRAS (Generally Recognised As Safe) non-pathogenic organisms. The company operates as a fully integrated pharmaceutical group covering R&D, manufacturing, marketing and global distribution across five therapeutic segments: Joint Care (anchored by the HYMOVIS product line for knee osteoarthritis, including the December 2025 FDA-approved HYMOVIS ONE), Skin Care, Eye Care (expanded via the Altacor acquisition), Specialty Care (including the Oncofid-P Phase III oncology pipeline for bladder cancer, plus Collagenase and HyCar development projects), and Health & Wellness Care (gynaecology, urology, dermatology via Meditrina).

The technology backbone rests on approximately 1,522 patents (1,259 of them HA-specific) and four Italian manufacturing sites: the 330,000 m² Abano Terme headquarters producing vials, ampoules, pre-filled syringes, eye drops, topical products and oral solids (annual capacity of 50M+ injectables, 115M+ topical units, 75M tablets/capsules, 6M pre-filled syringes); the Noto fermentation R&D and API site (AIFA-authorized since 2013); the Paderno Dugnano site for oral and dermal delivery systems (patches, plasters, lip products); and the Monte Giberto site for periocular gauzes and food supplements. Quality systems are certified to ISO 13485, ISO 9001, ISO 14001, ISO 22716, GMP and MDSAP, with US-market products additionally compliant with 21 CFR 211/820.

The business model combines branded pharmaceutical product sales, medical device sales, food supplement distribution (via Meditrina) and contract manufacturing services for third-party APIs, lyophilised vaccines and finished dosage forms. Distribution runs through wholly-owned subsidiaries, local partners and distributors in 120+ countries, supported by the Salesforce Life Sciences Cloud platform adopted in October 2025. FY2025 consolidated turnover reached €538.3 million (+5.5% y/y) with EBITDA of €110.1 million (+12.9% y/y), reflecting an 11% CAGR over 2020-2025 from €319.6 million. Geographic growth was led by Rest of World at +41.1% (including Indonesia and UK acquisitions), Europe at +17.7%, MENA at +15.3% and USA at +8.9%.

Name

Fidia Farmaceutici

Legal name

Fidia Farmaceutici S.p.A.

Website

https://fidiapharma.com

Company type

Private

Founded year

1946

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Fidia Farmaceutici is a privately held Italian pharmaceutical company founded in 1946 that develops, manufactures and globally distributes hyaluronic acid-based therapeutics across joint care, skin care, eye care, specialty care and health & wellness segments, reaching 120+ countries through subsidiaries and distributors.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI)

akta.pro secondary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Hyaluronic acid therapeutics
• Intra-articular injections
• Ophthalmic pharmaceuticals
• Pharmaceutical contract manufacturing
• Regenerative medicine products

Headquarters

HQ city

Abano Terme

HQ country

Italy

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue from medicinal products including hyaluronic acid-based therapeutics for joint care, skin care, eye care, and specialty care. Includes prescription pharmaceuticals and medical devices.
2. Medical Devices: Production and sale of medical devices including sterile injectables, topical products, eye drops, dermal delivery systems (patches, plasters, films), and periocular gauzes.
3. Food Supplements: Distribution of food supplements in gynaecology, urology and dermatology sectors through Meditrina Pharmaceuticals acquisition.
4. Contract Manufacturing: Third-party manufacturing services including production of HA on behalf of third parties, lyophilised vaccines, and various pharmaceutical forms.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Fidia Farmaceutici is a fully integrated Italian pharmaceutical company that develops, manufactures, and globally distributes hyaluronic acid (HA)-based therapeutics across Joint Care (e.g., HYMOVIS for knee osteoarthritis), Skin Care, Eye Care (e.g., Clinitas), Specialty Care (oncology, collagenase), and Health & Wellness segments. The company also offers pharmaceutical contract manufacturing services for injectables, topical products, pre-filled syringes, solid orals, eye drops, medicated plasters, and APIs at its Italian GMP-certified plants.

Product overview

Fidia Farmaceutici is a fully integrated pharmaceutical company founded in 1946, specializing in hyaluronic acid (HA) and its derivatives for therapeutic applications. The company manages the entire product lifecycle from R&D to manufacturing to marketing and sales. Their portfolio spans multiple therapeutic areas including Joint Care (with HYMOVIS® ONE for knee osteoarthritis), Skin Care, Eye Care (including Clinitas from acquired Altacor), Specialty Care (including Oncofid-P for bladder cancer, Collagenase for Dupuytren's contracture, and HyCar for arthritis), and Health & Wellness Care. In addition to proprietary pharmaceutical products, Fidia offers contract manufacturing services for injectables, topical products, pre-filled syringes, solid orals, eye drops, medicated plasters, and food supplements across their four Italian manufacturing sites.

Differentiator

Problem solved

Functional benefit

Brands

• HYMOVIS: HA-based intra-articular therapy for knee osteoarthritis treatment.
• Clinitas
• Oncofid-P
• Fidia Learning Lab

Products and services

• HYMOVIS ONE
• HYMOVIS product line

Quantifiable outcome

• Revenue growth of 5.5% y/y reaching €538.3 million in 2025
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and strategic acquisition.

• SalesforcecoreTechnology or Integration · 11 October 2025Fidia signed on as early adopter of Salesforce Life Sciences Cloud for Customer Engagement, an agent-first AI solution integrating sales, marketing, medical affairs, and reimbursement functions on a single compliant system. Built on Salesforce's Hyperforce infrastructure with HIPAA, GxP, and GDPR compliance. Became generally available on October 11, 2025.
• PfizercoreTechnology or Integration · 11 October 2025Pfizer also signed on as early adopter of Salesforce Life Sciences Cloud alongside Fidia, representing a co-adoption of the AI-powered customer engagement platform.
• Altacor Ltdstrategic acquisitionStrategic or Co-development Partner · 3 September 2025Acquisition of UK-based specialist ophthalmology company Altacor, marking Fidia's entry into the UK ophthalmology market. Altacor has a growing portfolio including Clinitas dry eye treatment product. This represents a strategic acquisition to expand operational capabilities and strengthen know-how in ophthalmology.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fidia-farmaceutici-spa
• Instagraminstagram.com/fidiafarmaceutici
• Xx.com/Fidiapharma

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fidia Farmaceutici